Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

675 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.
Zhao Y, Ma Y, Zang A, Cheng Y, Zhang Y, Wang X, Chen Z, Qu S, He J, Chen C, Jin C, Zhu D, Li Q, Liu X, Su W, Ba Y, Hao Y, Chen J, Zhang G, Qu S, Li Y, Feng W, Yang M, Liu B, Ouyang W, Liang J, Yu Z, Kang X, Xue S, Yang G, Yan W, Yang Y, Liu Z, Peng Y, Fanslow B, Huang X, Zhang L, Zhao H. Zhao Y, et al. Among authors: ba y. J Hematol Oncol. 2023 May 8;16(1):50. doi: 10.1186/s13045-023-01445-1. J Hematol Oncol. 2023. PMID: 37158938 Free PMC article. Clinical Trial.
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Huang DZ, Xiong JP, Xu N, Yan Z, Zhuang ZX, Yu Z, Wan HP, Zhang Y, Deng T, Zheng RS, Guo ZQ, Hu CH, Wang ML, Yu ZH, Yao Y, Meng JC, Ba Y. Huang DZ, et al. Among authors: ba y. Zhonghua Zhong Liu Za Zhi. 2012 Nov;34(11):865-8. doi: 10.3760/cma.j.issn.0253-3766.2012.11.015. Zhonghua Zhong Liu Za Zhi. 2012. PMID: 23291139 Clinical Trial. Chinese.
Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial.
Deng T, Xu N, Xiong JP, Yan Z, Zhuang ZX, Yu Z, Wan HP, Zhang Y, Huang DZ, Zheng RS, Guo ZQ, Hu CH, Wang ML, Yu ZH, Yao Y, Meng JC, Ba Y. Deng T, et al. Among authors: ba y. J Chemother. 2013 Feb;25(1):56-9. doi: 10.1179/1973947812Y.0000000057. J Chemother. 2013. PMID: 23433446 Clinical Trial.
Challenges in anticancer drug R&D in China.
Zhao S, Lv C, Gong J, Wenfeng F, Hu X, Ba Y, Xiaoyuan C, Zhimin Y, Shen L, Zhang L; Chinese Phase 1 Oncology trial Consortium. Zhao S, et al. Among authors: ba y. Lancet Oncol. 2019 Feb;20(2):183-186. doi: 10.1016/S1470-2045(18)30865-9. Lancet Oncol. 2019. PMID: 30723039 No abstract available.
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition).
Li J, Yuan Y, Yang F, Wang Y, Zhu X, Wang Z, Zheng S, Wan D, He J, Wang J, Ba Y, Bai C, Bai L, Bai W, Bi F, Cai K, Cai M, Cai S, Chen G, Chen K, Chen L, Chen P, Chi P, Dai G, Deng Y, Ding K, Fan Q, Fang W, Fang X, Feng F, Fu C, Fu Q, Gu Y, He Y, Jia B, Jiang K, Lai M, Lan P, Li E, Li D, Li J, Li L, Li M, Li S, Li Y, Li Y, Li Z, Liang X, Liang Z, Lin F, Lin G, Liu H, Liu J, Liu T, Liu Y, Pan H, Pan Z, Pei H, Qiu M, Qu X, Ren L, Shen Z, Sheng W, Song C, Song L, Sun J, Sun L, Sun Y, Tang Y, Tao M, Wang C, Wang H, Wang J, Wang S, Wang X, Wang X, Wang Z, Wu A, Wu N, Xia L, Xiao Y, Xing B, Xiong B, Xu J, Xu J, Xu N, Xu R, Xu Z, Yang Y, Yao H, Ye Y, Yu Y, Yu Y, Yue J, Zhang J, Zhang J, Zhang S, Zhang W, Zhang Y, Zhang Z, Zhang Z, Zhao L, Zhao R, Zhou F, Zhou J, Jin J, Gu J, Shen L. Li J, et al. Among authors: ba y. J Hematol Oncol. 2019 Feb 14;12(1):16. doi: 10.1186/s13045-019-0702-0. J Hematol Oncol. 2019. PMID: 30764882 Free PMC article. Review.
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Huang J, Xu B, Liu Y, Huang J, Lu P, Ba Y, Wu L, Bai Y, Zhang S, Feng J, Cheng Y, Li J, Wen L, Yuan X, Ma C, Hu C, Fan Q, Wang X. Huang J, et al. Among authors: ba y. Cancer Commun (Lond). 2019 Apr 2;39(1):16. doi: 10.1186/s40880-019-0359-7. Cancer Commun (Lond). 2019. PMID: 30940189 Free PMC article. Clinical Trial.
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.
Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH. Wang F, et al. Among authors: ba y. Ann Oncol. 2019 Sep 1;30(9):1479-1486. doi: 10.1093/annonc/mdz197. Ann Oncol. 2019. PMID: 31236579 Free PMC article. Clinical Trial.
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
Xu J, Xu RH, Qin S, Pan H, Bai Y, Chi Y, Wang L, Bi F, Cheng Y, Liu T, Ma D, Shen L, Ba Y, Liang J, Wang X, Yau TCC, Ma BB, Yeh KH, Lin JK, Kappeler C, Shapiro J, Kalmus J, Li J. Xu J, et al. Among authors: ba y. J Gastroenterol Hepatol. 2020 Aug;35(8):1307-1316. doi: 10.1111/jgh.14974. Epub 2020 Jan 28. J Gastroenterol Hepatol. 2020. PMID: 31900959 Free PMC article.
675 results